Key Management

Dr Paul MacLeman

Executive Chairman 

Paul brings decades of experience across the life sciences sector, including veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance.

He has expertise in capital raising, business development, technology commercialisation, and drug development. He has founded life sciences start-ups in the biologics area and worked in investment banking.

Previously served as Managing Director and/or CEO of several VC funded, ASX, NASDAQ and TSX listed companies. Paul is the current Chairman of AdAlta Limited (ASX:1AD). Fellow of the Australian Institute of Company Directors.

Dr David Foster

Managing Director 

Dr Foster has 20+ years experience in life sciences representing pharmaceutical, biotherapeutic and diagnostic companies, while in private legal practice.

He served as intellectual property counsel at Medarex, a mid-sized biotherapeutics company, acquired by Bristol-Myers Squibb.

Dr Foster co-founded Roberts Foster LLP - a technology focused law firm, bionorthTx- a regional life science trade association, and multiple private biotechnology companies.

He is a board member of bionorthTx and private biotechnology companies, and is a Member of Australian Institute of Company Directors.

He holds a Ph.D. from The University of Texas Southwestern Medical Center and J.D. from Golden Gate University School of Law.

Teresa Byrne

Vice President Clinical Product Development 

Teresa is an experienced Clinical Research Executive, with more than 20 years of pharmaceutical industry experience from the research bench to the clinic. She has experience in both large pharmaceutical companies as well as in smaller biotech companies and CRO organisations.

Teresa has held clinical operations leadership roles at Janssen Research & Development (a Johnson & Johnson company), Novartis Vaccines, and GlaxoSmithKline. In addition, Teresa served as the Director of Clinical Quality Assurance for BioMotiv, a biotech accelerator.

Most recently, she lead Clinical Development for Cersci Therapeutics, a small biotech company acquired by Acadia Pharmaceuticals.

Teresa holds a Bachelor of Arts in Biology from Rutgers University, has done post-graduate work in clinical pharmacology at Thomas Jefferson University, and is a certified GCP auditor.